Search Results - "Lippert, Joerg"

Immunogenicity of COVID-19 Tozinameran Vaccination in Patients on Chronic Dialysis by Schrezenmeier, Eva, Bergfeld, Leon, Hillus, David, Lippert, Joerg-Detlev, Weber, Ulrike, Tober-Lau, Pinkus, Landgraf, Irmgard, Schwarz, Tatjana, Kappert, Kai, Stefanski, Ana-Luisa, Sattler, Arne, Kotsch, Katja, Dörner, Thomas, Sander, Leif Erik, Budde, Klemens, Halleck, Fabian, Kurth, Florian, Corman, Victor Max, Choi, Mira

“…Patients with kidney failure have notoriously weak responses to common vaccines. Thus, immunogenicity of novel SARS-CoV-2 vaccines might be impaired in this…”
Get full text

Evaluation of the efficacy and safety of rivaroxaban using a computer model for blood coagulation by Burghaus, Rolf, Coboeken, Katrin, Gaub, Thomas, Kuepfer, Lars, Sensse, Anke, Siegmund, Hans-Ulrich, Weiss, Wolfgang, Mueck, Wolfgang, Lippert, Joerg

“…Rivaroxaban is an oral, direct Factor Xa inhibitor approved in the European Union and several other countries for the prevention of venous thromboembolism in…”
Get full text

Translational learning from clinical studies predicts drug pharmacokinetics across patient populations by Krauss, Markus, Hofmann, Ute, Schafmayer, Clemens, Igel, Svitlana, Schlender, Jan, Mueller, Christian, Brosch, Mario, von Schoenfels, Witigo, Erhart, Wiebke, Schuppert, Andreas, Block, Michael, Schaeffeler, Elke, Boehmer, Gabriele, Goerlitz, Linus, Hoecker, Jan, Lippert, Joerg, Kerb, Reinhold, Hampe, Jochen, Kuepfer, Lars, Schwab, Matthias

“…Early indication of late-stage failure of novel candidate drugs could be facilitated by continuous integration, assessment, and transfer of knowledge acquired…”
Get full text

Using expression data for quantification of active processes in physiologically based pharmacokinetic modeling by Meyer, Michaela, Schneckener, Sebastian, Ludewig, Bernd, Kuepfer, Lars, Lippert, Joerg

“…Active processes involved in drug metabolization and distribution mediated by enzymes, transporters, or binding partners mostly occur simultaneously in various…”
Get full text

Finerenone Dose–Exposure–Serum Potassium Response Analysis of FIDELIO-DKD Phase III: The Role of Dosing, Titration, and Inclusion Criteria by Goulooze, Sebastiaan Camiel, Snelder, Nelleke, Seelmann, Andreas, Horvat-Broecker, Andrea, Brinker, Meike, Joseph, Amer, Garmann, Dirk, Lippert, Joerg, Eissing, Thomas

“…Background Finerenone is a nonsteroidal selective mineralocorticoid receptor antagonist (MRA) that demonstrated efficacy in delaying the progression of chronic…”
Get full text

NT‐proBNP Qualifies as a Surrogate for Clinical End Points in Heart Failure by Schmitt, Walter, Rühs, Hauke, Burghaus, Rolf, Diedrich, Christian, Duwal, Sulav, Eissing, Thomas, Garmann, Dirk, Meyer, Michaela, Ploeger, Bart, Lippert, Jörg

“…N‐terminal pro‐B‐type natriuretic peptide (NT‐proBNP) is a well‐established biomarker in heart failure (HF) but controversially discussed as a potential…”
Get full text

Finerenone Dose-Exposure-Response for the Primary Kidney Outcome in FIDELIO-DKD Phase III: Population Pharmacokinetic and Time-to-Event Analysis by van den Berg, Paul, Ruppert, Martijn, Mesic, Emir, Snelder, Nelleke, Seelmann, Andreas, Heinig, Roland, Joseph, Amer, Garmann, Dirk, Lippert, Joerg, Eissing, Thomas

“…Background Finerenone is a nonsteroidal selective mineralocorticoid receptor antagonist that recently demonstrated efficacy in delaying chronic kidney disease…”
Get full text

Population Pharmacokinetic and Exposure–Response Analysis of Finerenone: Insights Based on Phase IIb Data and Simulations to Support Dose Selection for Pivotal Trials in Type 2 Diabetes with Chronic Kidney Disease by Snelder, Nelleke, Heinig, Roland, Drenth, Henk-Jan, Joseph, Amer, Kolkhof, Peter, Lippert, Jörg, Garmann, Dirk, Ploeger, Bart, Eissing, Thomas

“…Background Finerenone (BAY 94-8862) is a potent non-steroidal, selective mineralocorticoid receptor antagonist being developed for the treatment of patients…”
Get full text

Dose–Exposure–Response Analysis of the Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone on UACR and eGFR: An Analysis from FIDELIO-DKD by Goulooze, Sebastiaan Camiel, Heerspink, Hiddo J. L., van Noort, Martijn, Snelder, Nelleke, Brinker, Meike, Lippert, Joerg, Eissing, Thomas

“…Background and Objective Finerenone reduces the risk of kidney failure in patients with chronic kidney disease and type 2 diabetes. Changes in the urine…”
Get full text

Evolution of a detailed physiological model to simulate the gastrointestinal transit and absorption process in humans, part 1: oral solutions by Thelen, Kirstin, Coboeken, Katrin, Willmann, Stefan, Burghaus, Rolf, Dressman, Jennifer B, Lippert, Jörg

“…To enable more precise prediction of oral drug absorption, an existing physiologically based absorption model was revised. The revised model reflects detailed…”
Get more information

Predictive Pediatric Modeling and Simulation Using Ontogeny Information by Ince, Ibrahim, Solodenko, Juri, Frechen, Sebastian, Dallmann, André, Niederalt, Christoph, Schlender, Jan, Burghaus, Rolf, Lippert, Jörg, Willmann, Stefan

“…Food and Drug Administration submissions of physiologically based pharmacokinetic (PBPK) modeling and simulation of small‐molecule drugs document the relevance…”
Get full text

Trade in live reptiles, its impact on wild populations, and the role of the European market by Auliya, Mark, Altherr, Sandra, Ariano-Sanchez, Daniel, Baard, Ernst H., Brown, Carl, Brown, Rafe M., Cantu, Juan-Carlos, Gentile, Gabriele, Gildenhuys, Paul, Henningheim, Evert, Hintzmann, Jürgen, Kanari, Kahoru, Krvavac, Milivoje, Lettink, Marieke, Lippert, Jörg, Luiselli, Luca, Nilson, Göran, Nguyen, Truong Quang, Nijman, Vincent, Parham, James F., Pasachnik, Stesha A., Pedrono, Miguel, Rauhaus, Anna, Córdova, Danny Rueda, Sanchez, Maria-Elena, Schepp, Ulrich, van Schingen, Mona, Schneeweiss, Norbert, Segniagbeto, Gabriel H., Somaweera, Ruchira, Sy, Emerson Y., Türkozan, Oguz, Vinke, Sabine, Vinke, Thomas, Vyas, Raju, Williamson, Stuart, Ziegler, Thomas

“…Of the 10,272 currently recognized reptile species, the trade of fewer than 8% are regulated by the Convention on International Trade in Endangered Species of…”
Get full text

Front Cover by Eissing, Thomas, Goulooze, Sebastiaan Camiel, van den Berg, Paul, van Noort, Martijn, Ruppert, Martijn, Snelder, Nelleke, Garmann, Dirk, Lippert, Joerg, Heinig, Roland, Brinker, Meike, Heerspink, Hiddo J. L.

Get full text

Using real-world data in pediatric clinical trials: Lessons learned and future applications in studies of persistent pulmonary hypertension of the newborn by Miller, Thomas F., Kaiser, Andreas, Schmelter, Thomas, Lippert, Joerg, Davis, Jonathan M.

“…Persistent pulmonary hypertension of the newborn (PPHN) is a complication of term birth, characterized by persistent hypoxemia secondary to failure of normal…”
Get full text

Integrating cellular metabolism into a multiscale whole-body model by Krauss, Markus, Schaller, Stephan, Borchers, Steffen, Findeisen, Rolf, Lippert, Jörg, Kuepfer, Lars

“…Cellular metabolism continuously processes an enormous range of external compounds into endogenous metabolites and is as such a key element in human…”
Get full text

A generic whole body physiologically based pharmacokinetic model for therapeutic proteins in PK-Sim by Niederalt, Christoph, Kuepfer, Lars, Solodenko, Juri, Eissing, Thomas, Siegmund, Hans-Ulrich, Block, Michael, Willmann, Stefan, Lippert, Jörg

“…Proteins are an increasingly important class of drugs used as therapeutic as well as diagnostic agents. A generic physiologically based pharmacokinetic (PBPK)…”
Get full text

Development of a Paediatric Population-Based Model of the Pharmacokinetics of Rivaroxaban by Willmann, Stefan, Becker, Corina, Burghaus, Rolf, Coboeken, Katrin, Edginton, Andrea, Lippert, Jörg, Siegmund, Hans-Ulrich, Thelen, Kirstin, Mück, Wolfgang

“…Background Venous thromboembolism has been increasingly recognised as a clinical problem in the paediatric population. Guideline recommendations for…”
Get full text

Quantitative Systems Pharmacology Approaches for Immuno‐Oncology: Adding Virtual Patients to the Development Paradigm by Chelliah, Vijayalakshmi, Lazarou, Georgia, Bhatnagar, Sumit, Gibbs, John P., Nijsen, Marjoleen, Ray, Avijit, Stoll, Brian, Thompson, R. Adam, Gulati, Abhishek, Soukharev, Serguei, Yamada, Akihiro, Weddell, Jared, Sayama, Hiroyuki, Oishi, Masayo, Wittemer‐Rump, Sabine, Patel, Chirag, Niederalt, Christoph, Burghaus, Rolf, Scheerans, Christian, Lippert, Jörg, Kabilan, Senthil, Kareva, Irina, Belousova, Natalya, Rolfe, Alex, Zutshi, Anup, Chenel, Marylore, Venezia, Filippo, Fouliard, Sylvain, Oberwittler, Heike, Scholer‐Dahirel, Alix, Lelievre, Helene, Bottino, Dean, Collins, Sabrina C., Nguyen, Hoa Q., Wang, Haiqing, Yoneyama, Tomoki, Zhu, Andy Z.X., Graaf, Piet H., Kierzek, Andrzej M.

“…Drug development in oncology commonly exploits the tools of molecular biology to gain therapeutic benefit through reprograming of cellular responses. In…”
Get full text

Integration of dissolution into physiologically-based pharmacokinetic models III: PK-Sim by Willmann, Stefan, Thelen, Kirstin, Lippert, Jörg

“…Objectives  In‐silico methods are a cost‐effective possibility to support decision making at different stages of the drug development process. Among the…”
Get full text

Robust PBPK/PD-Based Model Predictive Control of Blood Glucose by Schaller, Stephan, Lippert, Jorg, Schaupp, Lukas, Pieber, Thomas R., Schuppert, Andreas, Eissing, Thomas

“…Goal: Automated glucose control (AGC) has not yet reached the point where it can be applied clinically [3]. Challenges are accuracy of subcutaneous (SC)…”
Get full text